GoodRx Holdings, Inc. 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K was filed by GoodRx Holdings, Inc. on September 22, 2022. The report discloses specific executive compensation adjustments approved by the Board of Directors.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on personnel compensation matters.
Material Changes
The Board approved retroactive compensation increases effective July 1, 2022, for two senior executives:
- Karsten Voermann (CFO): Annual base salary increased from $428,000 to $450,000. Target bonus opportunity increased from 30% to 100% of annual base salary.
- Babak Azad (CMO and SVP, Marketing & Communications): Annual base salary increased from $333,000 to $400,000.
Guidance, Outlook, and Risks
The filing text does not provide a clear value for guidance, outlook, management commentary, risks, contingencies, or unusual items beyond the disclosed compensation changes.
Investor Verification Checklist
- Verify the effective date of the compensation changes (July 1, 2022) against payroll records.
- Review the impact of the increased target bonus opportunity for the CFO on future compensation expense.
- Confirm the total annualized compensation cost for the affected executives post-adjustment.